Johnson & Johnson MedTech recently launched their Cereglide 92 catheter system for the treatment of acute ischemic stroke.

The burden of cardiovascular diseases among smokers is profoundly evident. Cigarette smoking, a leading preventable cause of morbidity and mortality, exerts a particularly pernicious impact on the ...

The challenges of translating neuroprotective interventions with promising efficacy in animal studies into effective treatments for patients with stroke are well documented, with issues including ...

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Johnson & Johnson MedTech (NYSE: JNJ) announced today that it launched the CereGlide 92 catheter system for treating acute ...

The following is a summary of “Hyponatremia is associated with malignant brain edema after mechanical thrombectomy in acute ...

Portable point-of-care blood tests, done by EMS before hospital arrival, need validation but could guide treatment and ...

Stroke experts from UCSF Health presented new research and clinical findings at the annual the American Stroke Association’s International Stroke Conference (ISC25), the world’s premier meeting ...

Researchers continue to advance the science to determine best treatments for stroke. Based on an international study of 530 patients, researchers discovered that while the clot retrieval procedure ...

New research provides further evidence that thrombolysis benefits select patients with acute ischemic stroke up to 24 hours after symptom onset.